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ABSTRACT  
The development of high-resolution nanosized photoacoustic contrast agents is an exciting yet challenging technological 
advance. Herein, antibody (breast cancer-associated antigen 1 (Brcaa1) monoclonal antibody)- and peptide (RGD)- 
functionalized gold nanoprisms (AuNprs) were used as a combinatorial methodology for in situ photoacoustic imaging, 
angiography, and localized hyperthermia using orthotopic and subcutaneous murine gastric carcinoma models. RGD-
conjugated PEGylated AuNprs are available for tumor angiography, and Brcaa1 monoclonal antibody-conjugated 
PEGylated AuNprs are used for targeting and for in situ imaging of gastric carcinoma in orthotopic tumor models. In situ 
photoacoustic imaging allowed for anatomical and functional imaging at the tumor site. In vivo tumor angiography imaging 
showed enhancement of the photoacoustic signal in a time-dependent manner. Furthermore, photoacoustic imaging 
demonstrated that tumor vessels were clearly damaged after localized hyperthermia. This is the first proof-of-concept using 
two AuNprs probes as highly sensitive contrasts and therapeutic agents for in situ tumor detection and inhibition. These 
smart antibody/peptide AuNprs can be used as an efficient nanotheranostic platform for in vivo tumor detection with high 
sensitivity, as well as for tumor targeting therapy, which, with a single-dose injection, results in tumor size reduction and 
increases mice survival after localized hyperthermia treatment. 
Keywords: Photoacoustic imaging; Angiography; Tumor targeting; Hyperthermia; Gastric cancer; Theranostics. 
 
1 Introduction 
Since Richard Feynman’s famous talk, “There's plenty of room at the bottom” at an American Physical Society 
meeting at Caltech in 1959 [1], nanotechnology has led to the development of new materials (e.g. nanoparticles 
(NPs)) and devices [2] with a wide-range of applications, especially in imaging, diagnostics, and therapy, contributing to 
the early detection and treatment of cancer and metastasis [3, 4]. NPs are within the same size domain as many 
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biomolecules, including enzymes, antibodies, and protein receptors. This, combined with the unique properties of materials 
in the nanosize range, provides scope for improved biomaterials for therapy and diagnostics. 
 
Since light absorption from biological tissue components is minimized at near-infrared (NIR) wavelengths, most NPs for 
in vivo imaging have been designed to strongly absorb in the NIR region so as to be effective contrast agents [5, 6]. Gold-
nanoprisms (AuNprs) have been extensively used in bioimaging owing to their ability to tune the plasmon resonance 
maximum further into the NIR region [7, 8]. More recently, Bao et al. reported the use of AuNprs as a novel contrast agent 
for the hybrid technique of photoacoustic imaging (PAI). The authors demonstrated an in silico electron tomographic 
reconstruction of such Au nanostructures, which showed promise for application in biomedical imaging, drug delivery, and 
photothermal therapy [9]. Light, as an electromagnetic wave, possesses the property of diffraction and diffusion, which 
inevitably confines its application in bioimaging of tumors. Localized imaging with both deep penetration and high 
resolution is still a challenge for other modalities such as optical imaging and ultrasound imaging. In PAI, a pulse of NIR 
laser light is used in resonance with the surface plasmon instead of a continuous NIR source. 
This technique causes rapid thermal expansion of the surrounding media and the generation of a sound wave that can be 
detected on the surface of the subject. The use of NIR reduces the amount of absorption that occurs by the light, however 
absorption of the light by various other organs is unavoidable [10]. 
Numerous systems using Au nanocages [11] or Au nanorods [12, 13] have been used as NIR contrastenhancing agents for 
photoacoustic tomography and to image their distribution when circulating in the vasculature of mice tissues, as well as to 
enhance the diagnostic power of optoacoustic imaging. Nevertheless, a dual AuNprs probe used as a combinatorial platform 
for photoacoustic angiography, localized hyperthermia using a subcutaneous, and an orthotopic murine gastric carcinoma 
model has never been reported so far. Although it is not a replacement for traditional surgery, radiotherapy, or 
chemotherapy, localized hyperthermia has been used in numerous animal tumor studies, producing significant synergies 
with a complementary role for treating cancer [14, 15]. Recently, Ambrosone et al. reported the use of hyperthermia using 
naked Au triangles that caused hyperthermia overexpression of heat shock protein hsp70 with concomitant cell necrosis in 
an invertebrate animal model (Hydra vulgaris) [8]. More recently, Han et al. reported glucose-functionalized AuNprs for 
photothermal therapy of cancer tissue [16]. However, the impact on the cancer cells and the structure, function, growth, 
and metabolism caused by a series of genetic changes using Au triangles in higher organisms remains unknown. 
Here, we report that RGD conjugated PEGylated (PEG/RGD)-AuNprs are available for tumor angiography and breast 
cancer-associated antigen 1 (Brcaa1) monoclonal antibody-conjugated PEGylated (PEG/ Brcaa1)-AuNprs are used for 
targeting and in situ imaging of gastric carcinoma in orthotopic tumor models with high resolution and efficiency rates 
(Fig. 1). In situ photoacoustic imaging allowed for high resolution of blood vessels at the tumor site, with an enhancement 
of the photoacoustic signal in a timedependent manner. This platform is the first proofof- concept, reporting two AuNprs 
probes used as high sensitivity contrasts and therapeutic agents for in situ PAI of gastric cancer, in vivo tumor detection, 
and inhibition. These smart and biocompatible PEG/RGDAuNprs and PEG/Brcaa1-AuNprs can be used as efficient and 
safe nanotheranostic platforms for high sensitivity in vivo tumor detection, as well as for tumor targeting, which results in 
tumor size reduction and increases mice survival after localized hyperthermia treatment. 
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Figure 1 AuNprs as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized 
hyperthermia. (a) Schematic illustration of the AuNprs functionalized with PEG and a cyclic RGD peptide (PEG/RGD-AuNprs) and 
their application in photoacoustic angiography and in targeted phototherapy in the tumor vessels. (b) Schematic illustration of the 
antibody Brcaa1-AuNprs and their application in in situ photoacoustic imaging of gastric tumors. 
2 Experimental 
2.1 Synthesis and characterization of functionalized 
PEGylated AuNprs 
The surfactant-free methods for synthesis and characterization of functionalized PEGylated AuNprs can be found in our 
previous publications [7, 9]. Briefly, before functionalization, AuNprs were washed in deionized (DI) water and suspended 
in 2- (morpholino)ethanesulfonic acid (MES; 0.1 M, pH 6.0) solution. 3-(3-Dimethylaminopropyl)-carbodiimide (EDC) 
and N-hydroxysulfosuccinimide (sulfo-NHS) were added to 300 μL of the PEGylated AuNpr solution in the reactive MES 
solution (0.1 M, pH = 6) and allowed to react for 30 min at room temperature with EDC and sulfo-NHS final concentrations 
of 40 and 35 mM, respectively. After the reaction, the buffer was replaced by phosphate-buffered saline (PBS, pH = 8.0) 
and an excess of RGD-4C (GL Biochem Shanghai Ltd, China) or 300 μL Brcaa1 [17] monoantibody (2 mg/mL) was added 
and incubated for 3 h at room temperature. The resulting PEGylated AuNprs were stored in the dark at 4 °C until further 
use. 
The absorbance spectra of AuNprs, PEG-AuNprs, and RGD-PEG-AuNprs were measured by a Varian Cary 50 UV–Vis 
spectrophotometer. The morphology of the AuNprs was evaluated using high-resolution transmission electron microscopy 
(TEM, JEOL, JEM- 2010) and field emission scanning electron microscopy (FESEM, Zeiss Ultra5). The photoacoustic 
signal acquisition was performed using 10 replicates at each wavelength (680, 700, 710, 808, and 950 nm) in a Nexus 128 
(Endra Nexus 128, USA) and analyzed by OsiriX imaging software (OsiriX Foundation, Genève, Switzerland). 
2.2 In vitro study of RGD-PEG-AuNprs 
Human gastric epithelial mucosa cell line, GES-1, and human gastric cancer cell line, MGC-803, were used as models. 
GES-1 cells were cultured in a 5% CO2-balanced air incubator at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. MGC-803 cells were cultured in RPMI 1640 
medium containing 10% FBS and 1% penicillin-streptomycin at 37 °C and in 5% CO2. GES-1 cells were first cultured to 
ARTICLE              
4 
 
60% confluency before trypsinized to 5,000/well and seeded in a 96-well cell culture plate. Cells were incubated overnight 
in a conventional cell culture environment. 
For the MTT assay, cells were incubated with 50, 100,150, and 200 μg/mL of naked AuNprs, PEG-AuNprs, RGD-PEG-
AuNprs, or AuNprs-Brcaa1 particles for 24 h. The absorbance was read at 570 nm and the cell viability was determined 
from the intensity ratio of the treated to non-treated control cells and shown as an average ± standard deviation (n = 5). 
For the TEM images, MGC-803 cells were incubated with RGD-AuNprs (50 μg/mL Au) for 24 h and collected. 
The cells were treated with 2.5% glutaraldehyde phosphate buffer and fixed overnight before being rinsed with 0.1 M PBS 
three times (15 min each), incubated in 1% osmium tetroxide for 2 h, and rinsed with 0.1 M phosphate three times (15 min 
each). 
Samples were dehydrated sequentially in 30% and 50% ethanol for 10 min, 70% ethanol containing 2% uranyl acetate, and 
finally stained overnight. Next, the samples were dehydrated in 70% and 90% ethanol for 10 min each, followed by 
incubation in a 90% acetone/90% ethanol (1:1 v/v) solution for 15 min and rinsed in 90% acetone for 15 min. Finally, the 
samples were rinsed with 100% acetone at room temperature three times, embedded with +812 epoxy with pure acetone 
(1:1 v/v) at room temperature for 1–2 h, followed by pure acetone +812 epoxy resin (1:2) at room temperature for 3–4 h, 
and finally embedded in epoxy resin overnight with 812. The following day, the samples were embedded in epoxy resin 
2–3 times every 4 h. The samples were cured at 37 °C overnight, then 45 °C for 12 h, and 60 °C for 48 h. With a microtome 
slice thickness of 70 nm and lead citrate staining, the samples were imaged for TEM (JEOL, JEM-2010). 
For cell viability after laser irradiation, MGC-803 cells were incubated with RGD-AuNprs for 24 h. Then, the cells were 
washed twice with PBS and irradiated with 980 nm laser light for 3 min at 2 W/cm2. After irradiation, the cells were stained 
with Trypan Blue. The control group was MGC-803 cells without NP treatment. 
2.3 Construction of murine gastric cancer models 
All animal experiments were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong 
University (NO.SYXK2007-0025). Female nude mice (nu/nu, 18 g, and 4 weeks old) were purchased from the Shanghai 
SLAC Laboratory Animal Co. Ltd and housed in an SPF grade animal center. Subcutaneous gastric cancer (GC) tissues at 
the exponential growth phase loaded in nude mice were resected aseptically. Necrotic tissues were cut away, and the 
remaining tumor tissues were scissor-minced into pieces around 1–2 mm in diameter in 4 °C Hanks’ balanced salt solution 
and each piece was adjusted to 30 mg using scissors. Before the surgery, all mice were fasting for at least 8 h. Mice were 
anesthetized with 5% trichloraldehyde hydrate (4 μL/g weight) and an incision was made through the left upper abdominal 
pararectal line and peritoneum. The stomach wall was carefully exposed, and a part of the serosal membrane (~2 mm in 
diameter) in the middle of the greater curvature of the glandular stomach was mechanically scratched with ophthalmic 
knives. A tumor piece of 30 mg was then fixed on the injured site of the serosal surface with OB glue (Guang Zhou Baiyun 
Ltd, China). The stomach was then returned to the peritoneal cavity, and the abdominal wall and skin were closed with 9-
0 ophthalmic sutures. The mice were kept on a warm electric blanket at 37 °C until analepsis and kept separately in an SPF 
environment. 
2.4 In vivo PAI study of murine gastric cancer models 
In vivo PAI was accomplished by a PA system (Endra Nexus 128, USA) with the excitation laser set at the bottom of a 
hemispherical bowl. For subcutaneous tumor models, mice were injected intraperitoneally with 5% chloral hydrate (w/v) 
and supplemented with 1%–2% isoflurane, an appropriate gas for anesthesia. Nude mice with GC xenografts (subcutaneous 
or orthotopic models) were intravenously injected with 100 μL of 1 mg/mL RGD-AuNprs or Brcaa1-AuNprs, respectively. 
The Nexus 128 system was equipped with high (for subcutaneous xenografts) or low positions (for orthotopic xenografts) 
for image acquisition. The following irradiation laser wavelengths were chosen to observe the in vivo PA signal of the 
xenografts: 680, 700, 710, 808, 950, and 710 nm. Data were collected after 1, 3, and 6 h. The PA signals, which were 
received by the ultrasonic transducers, were spirally distributed on the surface of the bowl before finally directed to 
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computational graphic reconstruction. Reconstruction of the 2D and 3D PA images was performed by OsiriX imaging 
software (OsiriX Foundation, Switzerland). 
2.5 NIR absorption digital high-definition infrared microscopic imaging and localized hyperthermia of murine 
subcutaneous tumor model of gastric cancer 
For in vitro measurements, the photothermal effect of AuNprs was evaluated via irradiation by a 980 nm laser (LOS-BLD-
0980-1.3W-C, Hi-Tech Optoelectronics Co., Ltd. China) and read by an oscillometer (34970A, Agilent, USA). Briefly, for 
in vivo applications, a trial group (GC xenograft mice transplanted subcutaneous tumor models) was injected with 100 μL 
of 1 mg/mL RGD-AuNprs via tail vein. After 2 h, the 980 nm laser was applied to irradiate the tumor site and the images 
of temperature variation at the tumor site were accomplished by the digital high-definition infrared microscopic imaging 
system (Ying Fu Photoelectric Technology Co. Ltd, Shanghai, China). The laser energy was 2 W/cm2 (read according to a 
standard curve, data not shown). 
2.6 Computed tomography (CT) imaging 
In order to compare with the PAI, nude mice with GC xenografts (subcutaneous or orthotopic models) were also 
intravenously injected with 100 μL of 1 mg/mL RGD-AuNprs and Brcaa1-AuNprs and used in CT and X-ray imaging. CT 
imaging (Latheta LCT200, Hitachi-Aloka, Japan) was used for in situ imaging with the tube voltage of 50 kVp and exposure 
time of 300 ms. For X-ray imaging (Carestream FX PRO, KODAK, USA), the exposure time was 15 s. 
2.7 Distribution and pathological analysis of RGDPEG- AuNprs in subcutaneous gastric cancer models 
For in situ models, tumors were removed 24 h after the injection of Brcaa1-AuNprs and fixed in 5% paraformaldehyde 
overnight before being embedded in paraffin for tissue sections. For immunofluorescence staining, Brcaa1 mouse anti-
human antibody (1 mg/mL concentration of 1:100) was used as the primary antibody and FITC-rabbit anti-mouse (Abcam, 
UK) as the secondary antibody (1:1,000). For in vivo biodistribution studies, nude mice with GC xenografts were 
intravenously injected with 100 μL of 1 mg/mL RGD-AuNprs before being sacrificed at 24 h and 6 weeks post-injection 
(n = 3/group). The heart, liver, spleen, lungs, kidneys, and tumor sites were collected and weighed. The tissues (50 mg) 
were digested with aqua regia under heating. The Au concentration in solution was determined by an iCAP 6000 
Radial(Thermo, USA). 
2.8 Statistical analysis 
Each experiment was repeated three times in duplicate if not stated otherwise. The results were presented as the mean ± 
SD. Statistical differences were evaluated using the t-test and considered significant at P < 0.05. 
3 Results and discussion 
In this study, antibody (Brcaa1 monoclonal antibody) and peptide (RGD) functionalized AuNprs were used as a 
combinatorial methodology for in situ photoacoustic imaging, angiography, and localized hyperthermia for gastric 
carcinoma. RGD peptides have been extensively investigated as cell adhesion peptides that are recognized by cell-surface 
receptors, such as integrin ανβ3. RGD peptide can mediate cell adhesion and proliferation and plays an important role in 
tumor angiogenesis and metastasis, being considerably upregulated in the endothelium during angiogenesis. Therefore, 
RGD represents a marker for malignancy [18] and has become a useful tool for the targeting of drugs and probes for 
functionalized imaging contrast agents [19, 20]. Brcaa1 was screened from a large number of clinical specimens associated 
with the breast cancer antigen gene. It was also demonstrated to have high expression in 65% of gastric cancer cells, and 
this expression increases with the progression of malignancy [17]. Therefore, the Brcaa1 monoclonal antibody was 
prepared and applied to target human gastric cancer cells [21, 22]. 
AuNprs coated with PEG-COOH, a cyclic peptide RGD-4C (Arg-Gly-Asp bicyclic peptide, ACDCRGDCFCG, disulfide 
bonds), and an antibody for Brcaa1 were characterized by TEM and UV–vis– NIR spectroscopy extinction. Figure 2(a) 
represents the TEM image of naked AuNprs. A nearly flat shape of an equilateral triangle with a side length of about 
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110 nm can be observed. UV–vis–NIR spectroscopy extinction spectra of naked RGD-conjugated PEGylated AuNprs are 
depicted in Fig. 2(b). Two distinct peaks around 980 and 530 nm can be observed with a slightly red-shifted peak for RGD-
conjugated PEGylated AuNprs.  
In order to normalize the AuNprs photoacoustic signals as a function of the concentration, the lowest concentration of 
AuNprs was selected as an internal reference solution, with an absorbance of approximately 0.05 OD. A linear relationship 
(R2 = 0.991) between the absorption at 710 nm and the concentration of the photoacoustic signal in relation to the AuNprs 
hemispherical photoacoustic detection system is represented in Fig. 2(c). 
To evaluate the thermal effects of AuNprs, the temperature of AuNprs in aqueous solution was evaluated over time using 
a 980-nm laser light source (Agilent digital thermocouple and logger detection) (Fig. 2(d)). Figure 2(d) shows the variation 
of temperature under 980 nm laser irradiation near the heating location ~1 cm from the area under laser illumination. Six 
different concentrations of AuNprs (0, 5, 10, 30, 75, 150, and 300 μg/mL) were applied. The temperature of the AuNprs 
solution increases to around 88 °C for the 300 μg/mL AuNprs under 0.3 W/cm2 irradiation for 5 min. At a moderate AuNprs 
concentration of 75 μg/mL, the ΔT reached 31 °C. These results clearly demonstrate that the prepared AuNprs have 
substantial thermal effects under low laser energy irradiation, which is the basis of their application as photoacoustic 
contrast agents and for hyperthermia treatment of cancer diseased cells. 
The cellular uptake of the AuNprs was characterized using TEM (Fig. S1 in the Electronic Supplementary Material (ESM)) 
and two-photon microscopy (Fig. S2 in the ESM). The TEM images show subcellular localization of the RGD-conjugated 
PEGylated AuNprs in MGC-803 cells (Fig. S1(a) in the ESM). RGDconjugated PEGylated AuNprs are distributed in the 
cytoplasm within the cell vesicles (Fig. S1(b) in the ESM). Under a 746 nm excitation laser, two-photon fluorescence 
microscopy showed that RGD-conjugated PEGylated AuNprs can easily reach the cytoplasm (in 24 h) of previously 
incubated MGC-803 cells (Fig. S2 in the ESM). White fluorescent dots observed in the cytoplasm of the cells indicate the 
intracellular uptake of the RGD-conjugated PEGylated AuNprs, whereas actin fibers are stained in red and Brcaa1-FITC 
in green and blue dots (Hoechst staining) indicate the nuclei of the cells. 
 
Figure 2 (a) TEM of AuNprs. (b) UV–vis–NIR spectra of AuNprs solution, PEGylated AuNprs, and RGD-AuNprs. (c) Dependence of 
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PA signals on the AuNprs concentration. (d) Dependence of temperature on AuNprs concentration under the irradiation time of 5 min 
at 0.3 W/cm2. 
 
The cytotoxicity of the antibody/peptide AuNprs was evaluated using the GES-1 cell line. An MTT assay was performed 
to assess the cell viability using increasing amounts of AuNprs without laser irradiation (Figs. S3 and S4 in the ESM). 
Increasing amounts (50, 100, 150, and 200 μg/mL) of PEG-coated, RGD-coated PEGylated AuNprs, Brcaa1-
antibodyconjugated PEGylated-AuNprs, as well as naked AuNprs were incubated with 5 × 103 cells for 24 h. The Brcaa1-
antibody-coated and RGD-coated PEGylated AuNprs showed nearly 100% cell viability with increasing concentration 
without light exposure. In addition, no noticeable cytotoxicity (<10%) was observed for naked AuNprs. Hydrodynamic 
light scattering (DLS) in water and zeta-potential data of all AuNprs-conjugates (naked AuNprs, PEG-AuNprs, RGD-
AuNprs, and Brcaa1- antibody-AuNprs) (Fig. S5 in the ESM), as well as the conjugation and quantification of Brcaa1 
antibody on the surface of the nanoprisms (Fig. S6 in the ESM) was also performed in order to corroborate appropriate 
functionalization of the studied biomolecules. 
In order to evaluate the cell structural integrity, MGC-803 cells incubated with RGD-coated PEGylated AuNprs were 
irradiated under 100 mW, 980 nm laser power for 3 min. The cells were stained with Trypan Blue and imaged by optical 
microscopy. Although the cell morphology at this magnification remained normal, an increase in membrane permeability 
in response to Trypan Blue (vital stain used to selectively color dead cells only) due to the thermal effects of NPs was 
observed only for cells incubated with RGD-coated PEGylated AuNprs, when compared to control cells without exposure 
(Fig. S7 in the ESM).  
In order to evaluate the full potential of the functionalized AuNprs for in vivo tumor targeting and angiography, an in vivo 
murine orthotopic model of gastric cancer was built. The tumor accumulation was characterized in MGC803 bearing mice 
by taking photoacoustic images after tail-vein administration of RGD-coated PEGylated AuNprs at a concentration of 1 
mg/mL. The best signal to noise ratio at a wavelength of 710 nm was selected and scanned. Using OsiriX software analysis, 
tumor vascular imaging was achieved via image acquisition for maximum density projection (MIP). Figure 3(a) shows in 
vivo photoacoustic images of subcutaneous transplanted tumors and sequential photoacoustic MIP frames of tumor blood 
vessels before and 1, 3, and 6 h after tail-vein injection of RGD-coated PEGylated AuNprs. 
Using the conventional Nexus 128 system, imaging the tumor vasculature and the blood vessels could only be achieved 
through endogenous injection of a contrast agent, such as hemoglobin or deoxyhemoglobin. In addition, the tumor edges 
could roughly be imaged in the outermost region of the tumor (i.e. closest to the skin layer). The interior of the blood 
vessels was not visible. After tail-vein injection of RGD-coated PEGylated AuNprs, the blood vessels at the tumor site 
were clearly imaged, with an enhancement of the photoacoustic signal in a time-dependent manner (Figs. 3(b)–3(d)). In 
addition, RGD peptide-specific ctargeting of the tumor angiogenesis could be observed using the optoacoustic imaging of 
solid tumors to monitor angiogenesis and cancer progression. In fact, 4 h after injection, the prepared RGD-conjugated 
PEGylated AuNprs accumulated at the tumor site, as observed in the 3D PAI images of the tumors (Fig. S8 in the ESM). 
Moreover, the thermal effect of RGD conjugated PEGylated NPs could be exploited to treat cancer-diseased cells [23]. 
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Figure 3 In vivo photoacoustic imaging study of subcutaneous transplanted tumors. (a)–(d) Sequential PA MIP frames after tailinjection 
with RGD-AuNprs. (a) Before injection with RGDAuNprs, (b) injection with RGD-AuNprs after 1 h, (c) injection with 
RGD-AuNprs after 3 h, (d) injection with RGD-AuNprs after 6 h. Scale bars: 1 mm. 
 
In order to evaluate the in situ functional targeting and imaging of gastric carcinoma, a second mouse model and a different 
functionalization of AuNprs were used. A gastric-cancer orthotopic mouse tumor model was developed and Brcaa1 
antibody-conjugated PEGylated AuNprs (PEG/Brcaa1-AuNprs) were produced. First, the MGC-803 cell line was used to 
build the subcutaneous tumor model in nude mice. After the formation of the tumor tissue, the tumor tissue stability in 
nude mice was passaged three more times in order to access and insert fresh tumor tissue blocks in nude stomach via an 
OB adhesive construction of orthotopic gastric tumor transplantation. The OB glue paste technique is commonly used to 
establish nude mouse human gastric cancer orthotopic transplantation models. The OB glue paste technique is easy to 
perform and the biological behaviors of the nude mice human gastric cancer orthotopic transplantation models established 
with this technique are similar to the natural processes of growth and metastasis of human gastric cancer [24]. After 
establishing the orthotopic model, the blood supply and stomach tissue can easily be built. Rapid tumor growth in mice can 
be maintained for about four weeks. Figures S9(a) and S9(b) in the ESM show the orthotopic tumor mass model after four 
weeks, in which the blood supply and tumor volume significantly increase compared with the primary surgery to establish 
the tumor model (Fig. S9(a) in the ESM). Four weeks after the OB surgery, mice were tail-vein injected with PEG/Brcaa1-
AuNprs and photoacoustic images were taken. Figure 4 and Fig. S10 in the ESM show the results for the photoacoustic 
imaging of mice without (Fig. 4(a) and Movie S1 in the 
ESM) and with intravenous injection of PEG-AuNprs after 24 h (Fig. 4(b) and Movie S2 in the ESM). As shown in Fig. 
4(a), the MIP of the photoacoustic signal was weak and chaotic with a major interference from hemoglobin when there 
was no injection of contrast agent. In contrast, when injected with PEG/Brcaa1- 
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AuNprs, the tumor image improved significantly and imaging of the surface blood vessels was possible (Fig. 4(b) and 
Movie S2 in the ESM). At this time (24 h), no signal differences or levels of development could be distinguished between 
the various body organs, and therefore, the tumor location could not be determined to accomplish functional imaging. 
Nevertheless, 24 h after injection of PEG/Brcaa1- AuNprs, a significant difference between blood vessels, organs, and the 
tumor site was observed (Fig. 4(c) and Movie S3 in the ESM). Surgical scars (showing an “X” shape), surgical nylon 
thread, and the gastric site (Fig. 4(c)) were easily displayed in photoacoustic imaging of PEG/Brcaa1-AuNprs treated mice. 
In addition, the signal from the gastric tissue site was more intense than the signal of surrounding organs such as the liver, 
proving that the PEG/Brcaa1-AuNprs effectively targets the gastric tumor site. 
The shape and appearance of the mouse gastric tissue anatomy is depicted in Figs. 4(e) and 4(f). Gastric tumor tissues of 
mice treated with PEG/Brcaa1-AuNprs were stained using Brcaa1 immunofluorescent antibody only. Figs. 4(g)–4(i) show 
immunofluorescence staining of Brcaa1 in pathological tumor tissue using FITClabeled goat anti-mouse secondary 
antibody, confirming the specificity of the PEG/Brcaa1-AuNprs targeting. 
These data prove that photoacoustic imaging can be used to overcome some of the disadvantages (i.e. radioactive conditions 
and poor resolution in soft tissues from CT/X-ray, poor resolution with deep penetration from NIR fluorescence imaging, 
or speckles of optical coherence tomography) of imaging modalities, and penetrate deeper with high-resolution imaging. 
Photoacoustic imaging in cancer detection has been mainly focused on melanoma models, subcutaneous tumor xenograft 
transplantation models, or in vitro lymphangiography [13]; however, detection is still confined to superficial parts of the 
body. Here, we could achieve in situ effective detection of tumor targeting with concomitant deep and high-resolution 
photoacoustic imaging of the tumor site. Most importantly, we could improve the visualization of surface acoustic imaging 
of diseased tissues, thus advancing the detection of internal organs of the targeted lesion. This method is not only capable 
of distinguishing the different organs, but also of achieving structural imaging of the tumor site and maximizing the signal 
to achieve functional imaging. Our method is now able to fully reflect the photoacoustic contrast advantage in cancer 
imaging. 
In order to validate these results, PEG/RGD-coated AuNprs were used in X-ray and PEG/Brcaa1-coated 
AuNprs in CT imaging. Owing to its high atomic number and its absorption of X-rays, Au is often used in X-ray and CT 
imaging. In fact, many studies have shown that targeted Au NPs can increase the resolution at the tumor site, but with 
significantly higher concentrations of contrast agents. Here, we used ~5 mg/kg Au in the mouse model, although CT based 
on Au NPs usually requires 40–50 mg/kg Au for in vivo tumor imaging [25, 26]. Therefore, PEG/RGD-coated AuNprs (1 
mg/mL in 100 μL) and PEG/Brcaa1-coated AuNprs (1 mg/mL in 100 μL) were intravenously injected in mice bearing 
gastric tumors, and X-ray and CT detection was performed. As shown in Fig. 5, 
X-ray imaging of the control group (no NP treatment) showed no effect on the tumor site (Fig. 5(a)), whereas the X-ray 
image with 1 mg/mL of PEG/RGD-coated AuNprs had a significantly enhanced signal (Fig. 5(b)). 
The same applies for CT imaging, in which PEG/Brcaa1-AuNprs (1 mg/mL in 100 μL) were also intravenously injected 
in mice. The CT image with 1 mg/mL of PEG/Brcaa1-AuNprs showed no significant difference in the in situ gastric portion 
(Fig. 5(d)) when compared to the control group (Fig. 5(c)). 
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Figure 4 Representative photoacoustic imaging of gastric orthotopic tumor after injection of Brcaa1-AuNprs. (a) No injection of probes. 
(b) Photoacoustic imaging of gastric orthotopic tumor with injection of AuNprs after 24 h. (c) In situ targeting photoacoustic imaging 
using intravenously injected PEG/Brcaa1-AuNprs after 48 h. (d) Image of scar and black surgical nylon thread. (e) and (f) Anatomical 
images of the localized gastric cancer tumor. (g)–(i) Immunohistochemical staining of tumor section from in situ gastric cancer tumor 
model. (g) DAPI staining of gastric tumor slides. (h) Immunofluorescence staining of Brcaa1 in human gastric tumor. (i) Merged image. 
Scale bar: 100 μm. 
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Figure 5 X-ray and micro CT imaging. (a) X-ray image of control group (no NP treatment). (b) X-ray image with 1 mg/mL of PEG/RGD-
coated AuNprs. (c) CT image of control group. (d) CT image with 1 mg/mL of Brcaa1-AuNprs. 
 
These data show that using a single-dose injection probe, photoacoustic imaging in a subcutaneous tumor model using 
PEG/RGD-coated AuNprs (see Fig. 3) and an in situ tumor model using PEG/Brcaa1-coated 
AuNprs (see Fig. 4) can achieve better sensitivity and resolution results than conventional X-ray and CT imaging with the 
same dose of Au NPs. In order to evaluate the localized hyperthermia effect mediated by the functionalized AuNprs, a 
subcutaneous gastric-cancer xenograft mice model was used. Mice were injected with 100 μL of 1 mg/mL 
PEG/RGD-coated AuNprs via tail-vein injection. A 980 nm NIR laser and a high-definition digital infrared thermal 
imaging system were used for thermal imaging 2 h after injection (Fig. 6). The tumor was exposed to the 980 nm laser at 
2 h post-injection (0.3 W/cm2, 5 min). Figure 6(a) represents the temperature variation at the tumor site from 0 to 5 min 
after laser irradiation. Figure 6(a1) represents a thermal image of the representative MGC-803 tumor-bearing mouse before 
the laser is turned on, when the skin surface temperature is only 25.9 °C. After irradiation for 100 (Fig. 6(a2)), 150 (Fig. 
6(a3)), and 200 s (Fig. 6(a4)), the average temperatures at the tumor site after radiation are 40.7, 57.6, and 71.1 °C, 
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respectively. Figure 6(b) shows the hyperthermia in vivo assay measuring temperature variation in the control (no NP 
exposure) and experimental (injection of 100 μL of 1 mg/mL PEG/RGDcoated AuNprs) groups. In each image, the average 
of seven temperature measurement points was taken (six points and one point in the center of the circumference selection). 
The temperature at the tumor site in the experimental group (PEG/RGD-coated 
AuNprs) reached a peak of 75 °C after 200 s of exposure, showing significant thermal effects when compared to the control 
group, where the highest temperature is 30 °C (Figs. 6(b) and 6(c)). Figures 6(c1) and 6(c2) represent the local tumor 
morphology after localized hyperthermia of the control and experimental groups, respectively. The tissue without treatment 
(Fig. 6(c1)) had a normal appearance of intact skin, whereas the tissue after irradiation of the tumor exhibited a dark color 
(Fig. 6(c2)). Comparative results from photoacoustic imaging experiments showed deformation of the blood vessels 
surrounding the tumor tissue after hyperthermia therapy with PEG/RGD-coated AuNprs (Fig. 5(d)), while the control group 
at the same irradiation dose showed no significant change in tumor blood vessels (Fig. 6(d)). These results confirm the 
high efficiency of PEG/RGD-AuNprs and PEG/ Brcaa1-AuNprs as a combinatorial-targeted therapy 
in thermal imaging and therapy. 
The contribution to mice survival from localized hyperthermia effects at the tumor site using PEG/ 
RGD-AuNprs was assessed by monitoring survival after 150 days. Animals treated with PEG/RGD-AuNprs survived 
significantly longer (Fig. 7(a)) than the control groups before and after therapy and PEG/RGDAuNprs group without 
therapy. The trends in prolonged survival from PEG/RGD-AuNprs after therapy treatment indicate that the observed 
survival extension of more than 85% could be attributed to the destruction of gastric cancer cells via localized hyperthermia. 
Moreover, we hypothesized that the increase in mice survival using PEG/RGD-AuNprs after therapy would also enhance 
the likelihood of observing a tumor size reduction. Therefore, monitoring the change in tumor size as a function of time 
after treatment with PEG/RGD-AuNprs associated with laser application revealed a significant decrease in tumor growth 
(P < 0.005) at 27 days post AuNprs treatment (Fig. 7(b)) with a single-dose injection. After 35 days, animals treated with 
PEG/RGD-AuNprs after hyperthermia therapy show a tumor size of 22.1% ± 7.6%, compared to 100% ± 15.1% and 80.1% 
± 14.6% for control groups before and after treatment, respectively, and 90.0% ± 9.6% for PEG/RGD-AuNprs before 
therapy. 
 
The improved outcome in gastric tumor-bearing mice receiving PEG/RGD-AuNprs treatment strongly supports the 
extraordinary potential of these NPs as adjuvant agents to anticancer therapies. The safety and biodistribution of 
PEG/RGD-AuNprs was confirmed by ex vivo organ inductively coupled plasma mass spectrometry (ICP-MS) for 6 h and 
14 days after injection of the probes. The results show that 6 h after injection, PEG/RGD-AuNprs were mainly accumulated 
in the liver, kidney, lung, and tumor. After 14 days, the Au content decreased in most of the tissues and organs, especially 
in the heart and kidney (Fig. 7(c)). 
 
To validate the safety assessment, 14 days after injection of PEG/RGD-AuNprs, organs were harvested from mice and 
H&E stained for routine pathological analysis (Fig. 7(d)). H&E staining shows that in vivo administration of PEG/RGD-
AuNprs did not damage to several organs (i.e. lung, liver, kidney, spleen, or heart) when compared to the control group 
(without AuNpr administration). The lungs showed a clear and complete alveolar structure, a uniform distribution of the 
nucleus and cytoplasm was observed in liver tissue, the kidney tubules and glomeruli showed no obvious lesions, and the 
spleen showed normal white and red pulp distribution. Moreover, a normal cardiac morphology and intracellular free grainy 
was observed in the heart. 
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Figure 6 In vivo photothermal therapy study using intravenously injected RGD-AuNprs. (a) Thermal images of representative MGC-
803 tumor-bearing mouse exposed to 980 nm laser (0.3 W/cm2) for 3 min at 1 h post-injection of RGD-AuNprs. (b) Tumor heating 
curves of the PBS and RGD-AuNprs injected mice groups. (c) Localized tumor images of mice after 3 min exposure to laser. (c1): 
control group, (c2): experimental group. (d) Photoacoustic image of angiography for control group injected with PBS and for 
experimental group injected with PEG/RGD-coated AuNprs monitoring before and after tumor therapy. 
 
4 Conclusions 
Traditional imaging techniques are frequently limited by narrow penetration, low sensitivity, low specificity, and poor 
spatial resolution. Hybrid modalities such as optoacoustic imaging, an emerging molecular imaging modality, have greatly 
contributed to improving most of these limitations. 
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In summary, we developed a hybrid approach for both photoacoustic angiography and localized hyperthermia using 
antibody/peptide AuNprs in a subcutaneous and an orthotopic murine gastric carcinoma model. This system proved to be 
highly efficient for in situ photoacoustic imaging, with high-resolution of blood vessels at the tumor site and an 
enhancement of the photoacoustic signal coupled to localized hyperthermia. With a single-dose injection, these smart 
antibody/peptide AuNprs are responsible for an extensive tumor size reduction and increase in mice survival after localized 
hyperthermia treatment. 
This is the first proof-of-concept using two AuNprs probes as high sensitivity contrasts and therapeutic agents for in vivo 
tumor detection and inhibition, which can be used as an efficient and safe nanotheranostic platform. Taken together, the 
results reported herein establish the mechanism of action of AuNprs in both imaging and targeting approaches, as well as 
the relationship between hyperthermia time, intensity, and efficacy in an in vivo mouse model, which will translate in a 
very meaningful way to cancer clinical research. 
 
Figure 7 Therapeutic outcome following treatment with PEG/RGD AuNprs in subcutaneous transplanted gastric tumors. (a) Kaplan- 
Meier survival curves during 150 days of control mice (no NP treatment) and for PEG/RGD AuNprs before and after localized 
hyperthermia therapy. (b) Relative tumor size in mice bearing gastric tumor xenografts treated with PEG/RGD AuNprs before and after 
localized hyperthermia therapy and compared to control groups. (c) ICP-MS of Au content at 6 h and 14 days after injection with 
PEG/RGD-AuNprs (n = 3). (d) H&E stained tissue sections of the organs (i.e. lung, liver, kidney, spleen, heart) collected from mice 20 
days after intravenous injection of a single dose of PEG/RGD-AuNprs. Bar: 50 μm. 
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